Genprex Secures Canadian Patent for Reqorsa Lung Cancer Therapy
GNPX sits 47% above its 52-week low of $0.423 on elevated volume (2.5× avg).
Summary
Genprex announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for a patent covering its Reqorsa® Gene Therapy for lung cancer, strengthening its intellectual property portfolio.
Key Events · Product Development and Regulatory · GNPX
-
Canadian Patent Allowance
Genprex received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering Reqorsa® Gene Therapy in combination with PD-1 or PD-L1 antibodies for non-small cell and small cell lung cancer.
-
IP Portfolio Expansion
This patent expands on previously granted patents for REQORSA in combination with PD-1 and PD-L1 antibodies in other major regions, including the U.S., Japan, and Europe.
-
Supports Clinical Trials
The company believes this patent provides crucial protection for the therapeutic combinations currently being evaluated in its Acclaim-3 clinical trial.
Analysis · GNPX · Life Sciences
This patent allowance strengthens Genprex's intellectual property for its lead gene therapy, Reqorsa, in a significant market. For a company currently facing Nasdaq delisting threats and a 'going concern' warning, securing IP protection for its core asset is a positive development that reinforces the long-term value proposition of its pipeline, even as it navigates immediate financial challenges.
At the time of this filing, GNPX was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.5M. The 52-week trading range was $0.42 to $55.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.